Epigenomics AG / Key word(s): Corporate Action
30.08.2013 15:40
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, Germany, August 30, 2013 - Epigenomics AG (ISIN: DE000A1K0516)
announces that upon registration of the conditional capital of the Company
today successfully completed the issuance of convertible bonds with a
nominal amount of EUR 500,000. These convertible bonds constitute the first
tranche of a total issuance of up to EUR 5m guaranteed by an agreement
between YA Global Master SPV Ltd. ('YA Global') and the Company. Following
successful conversion or repayment of already issued tranches, the
issuance of possible further tranches will be subject to future
discretionary decisions by the Executive Board of the Company.
Excluding pre-emptive rights to existing shareholders, the convertible
bonds will be issued to YA Global exclusively at a subscription price of
95% of the nominal amount. The bonds carry no interest, have a term until
May 29, 2014 and are convertible into shares of Epigenomics immediately
upon their issuance at the full discretion of the bearer of the bonds. The
conversion price equals the average trading price of Epigenomics shares
during a 5 day period prior to the time of conversion less a 5% discount,
but cannot be lower than EUR 2.10.
Further details regarding the terms and conditions in connection with the
issuance of convertible bonds according to the agreement with YA Global
were announced by the ad hoc notification dated August 18, 2013.
- End of Ad hoc -
Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com
Epigenomics' legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG and
its business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Epigenomics AG is
providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.
30.08.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
30. August 2013 - 0:00 (CEST)